Loading...

Ramez Eskander

TitleAssistant Clinical Professor
InstitutionUniversity of California San Diego
DepartmentReproductive Medicine
Address9500 Gilman Drive #0987
La Jolla CA 92093
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Eskander RN. The Epigenetic Landscape in the Treatment of Gynecologic Malignancies. Am Soc Clin Oncol Educ Book. 2018 May 23; (38):480-487. PMID: 30231335.
      View in: PubMed
    2. Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 Mar 15. PMID: 29550184.
      View in: PubMed
    3. Taylor KN, Eskander RN. PARP inhibitors in epithelial ovarian cancer. Recent Pat Anticancer Drug Discov. 2017 Dec 03. PMID: 29205122.
      View in: PubMed
    4. Alldredge JK, Eskander RN. EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. Gynecol Oncol Res Pract. 2017; 4:17. PMID: 29093822.
      View in: PubMed
    5. Clair K, Wolford J, Veran-Taguibao S, Kim G, Eskander RN. Primary low-grade endometrial stromal sarcoma of the omentum. Gynecol Oncol Rep. 2017 Aug; 21:119-121. PMID: 28831418.
      View in: PubMed
    6. Paraghamian SE, Longoria TC, Eskander RN. Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Gynecol Oncol Res Pract. 2017; 4:3. PMID: 28174665.
      View in: PubMed
    7. Eskander RN, Carpenter BA, Wu HG, Wolf JK. The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients. Curr Med Res Opin. 2016 06; 32(6):1161-5. PMID: 27052730.
      View in: PubMed
    8. Longoria TC, Eskander RN. Erratum to: Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2016; 3:2. PMID: 27232495; PMCID: PMC4881200.
    9. Eskander RN, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, Monk BJ, Walker JL, Eisenhauer E, Hoang BH. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2016 Jan; 26(1):125-32. PMID: 26397159.
      View in: PubMed
    10. Longoria TC, Eskander RN. Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2015; 2:11. PMID: 27231571; PMCID: PMC4881063.
    11. Tewari KS, Eskander RN, Monk BJ. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3829-35. PMID: 26169965.
      View in: PubMed
    12. Grove N, Zheng M, Bristow RE, Eskander RN. Extensive Tattoos Mimicking Lymphatic Metastasis on Positron Emission Tomography Scan in a Patient With Cervical Cancer. Obstet Gynecol. 2015 Jul; 126(1):182-5. PMID: 25923020.
      View in: PubMed
    13. Ji T, Guo Y, Kim K, McQueen P, Ghaffar S, Christ A, Lin C, Eskander R, Zi X, Hoang BH. Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma. Mol Cancer. 2015 Apr 17; 14:86. PMID: 25890345; PMCID: PMC4411772.
    14. Cripe J, Eskander R, Tewari K. Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review. World J Clin Oncol. 2015 Apr 10; 6(2):16-21. PMID: 25866706; PMCID: PMC4390890.
    15. Eskander RN, Lynch HT, Brown SM, Wagman LD, Tewari KS. Novel MSH2 Mutation in the First Report of a Vietnamese-American Kindred with Lynch Syndrome. Gynecol Oncol Rep. 2015 Apr; 12:31-3. PMID: 26076155; PMCID: PMC4442652.
    16. Longoria TC, Eskander RN. Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer. Recent Pat Anticancer Drug Discov. 2015; 10(2):133-44. PMID: 25938471.
      View in: PubMed
    17. Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol. 2015; 11(6):909-22. PMID: 25760973.
      View in: PubMed
    18. Eskander RN, Tewari KS. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. Clin Ther. 2015 Jan 01; 37(1):20-38. PMID: 25592089.
      View in: PubMed
    19. Eskander RN, Chang J, Ziogas A, Anton-Culver H, Bristow RE. Evaluation of 30-day hospital readmission after surgery for advanced-stage ovarian cancer in a medicare population. J Clin Oncol. 2014 Dec 20; 32(36):4113-9. PMID: 25385738; PMCID: PMC4517941.
    20. Eskander RN, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol. 2014 Nov; 6(6):280-92. PMID: 25364393; PMCID: PMC4206649.
    21. Eskander RN, Tewari KS. Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Expert Rev Clin Pharmacol. 2014 Nov; 7(6):847-58. PMID: 25301678.
      View in: PubMed
    22. Cripe J, Tseng J, Eskander R, Fader AN, Tanner E, Bristow R. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality. Ann Surg Oncol. 2015 Feb; 22(2):655-61. PMID: 25155402.
      View in: PubMed
    23. Ji T, Eskander R, Wang Y, Sun K, Hoang BH, Guo W. Can surgical management of bone metastases improve quality of life among women with gynecologic cancer? World J Surg Oncol. 2014 Aug 05; 12:250. PMID: 25091036; PMCID: PMC4125343.
    24. Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol. 2014 Aug; 26(4):314-21. PMID: 24979076.
      View in: PubMed
    25. Eskander RN, Tewari KS. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol. 2014 Jul; 25(3):249-59. PMID: 25045438; PMCID: PMC4102744.
    26. Eskander RN, Tewari KS. PARP inhibition and synthetic lethality in ovarian cancer. Expert Rev Clin Pharmacol. 2014 Sep; 7(5):613-22. PMID: 24984781.
      View in: PubMed
    27. Long B, Eskander RN, Tewari KS. Use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A review. World J Radiol. 2014 Jun 28; 6(6):366-73. PMID: 24976937; PMCID: PMC4072821.
    28. Eskander RN, Osann K, Dickson E, Holman LL, Rauh-Hain JA, Spoozak L, Wu E, Krill L, Fader AN, Tewari KS. Assessment of palliative care training in gynecologic oncology: a gynecologic oncology fellow research network study. Gynecol Oncol. 2014 Aug; 134(2):379-84. PMID: 24887355; PMCID: PMC4191825.
    29. Eskander RN, Cripe J, Bristow RE. Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise. Curr Treat Options Oncol. 2014 Mar; 15(1):27-40. PMID: 24338278.
      View in: PubMed
    30. Eskander RN, Tewari KS. American Society of Clinical Oncology 2013: summary of scientific advancements in gynecologic cancer. Int J Gynecol Cancer. 2014 Jan; 24(1):13-8. PMID: 24300468; PMCID: PMC3907666.
    31. Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014 Feb; 132(2):496-505. PMID: 24316305.
      View in: PubMed
    32. Eskander RN, Tewari KS. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol. 2013 Oct 03; 5(Suppl 1):55-61. PMID: 24124397; PMCID: PMC3795053.
    33. Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer. 2013 Jul; 23(6):997-1005. PMID: 23792601; PMCID: PMC3694282.
    34. Ji T, Lin C, Krill LS, Eskander R, Guo Y, Zi X, Hoang BH. Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Mol Cancer. 2013 Jun 10; 12:55. PMID: 23764122; PMCID: PMC3681603.
    35. Eskander RN, Baruah J, Nayak R, Brueseke T, Ji T, Wardeh R, Tewari KS. Outside slide review in gynecologic oncology: impact on patient care and treatment. Int J Gynecol Pathol. 2013 May; 32(3):293-8. PMID: 23518913.
      View in: PubMed
    36. Lin CH, Guo Y, Ghaffar S, McQueen P, Pourmorady J, Christ A, Rooney K, Ji T, Eskander R, Zi X, Hoang BH. Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma. 2013; 2013:147541. PMID: 23476112; PMCID: PMC3582188.
    37. Eskander RN, Tewari KS. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health. 2012; 4:395-404. PMID: 22927770; PMCID: PMC3422105.
    38. Dellinger TH, Planutis K, Jandial DD, Eskander RN, Martinez ME, Zi X, Monk BJ, Holcombe RF. Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer. Gynecol Oncol. 2012 Aug; 126(2):259-67. PMID: 22555103; PMCID: PMC3688285.
    39. Eskander RN, Randall LM, Sakai T, Guo Y, Hoang B, Zi X. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J Obstet Gynaecol Res. 2012 Aug; 38(8):1086-94. PMID: 22540374; PMCID: PMC3405181.
    40. Sakai T, Eskander RN, Guo Y, Kim KJ, Mefford J, Hopkins J, Bhatia NN, Zi X, Hoang BH. Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. J Orthop Res. 2012 Jul; 30(7):1045-50. PMID: 22213202; PMCID: PMC3685290.
    41. Eskander RN, Tarsa M, Herbst KD, Kelly TF. Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy. J Obstet Gynaecol Res. 2011 Nov; 37(11):1731-3. PMID: 21790885.
      View in: PubMed
    42. Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011 Aug; 205(2):103-10. PMID: 21411052.
      View in: PubMed
    43. Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics. 2011; 5:1-5. PMID: 21383911; PMCID: PMC3044789.
    44. Eskander RN, Scanderbeg D, Saenz CC, Brown M, Yashar C. Comparison of computed tomography and magnetic resonance imaging in cervical cancer brachytherapy target and normal tissue contouring. Int J Gynecol Cancer. 2010 Jan; 20(1):47-53. PMID: 20130502.
      View in: PubMed
    45. Warshak CR, Ramos GA, Eskander R, Benirschke K, Saenz CC, Kelly TF, Moore TR, Resnik R. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol. 2010 Jan; 115(1):65-9. PMID: 20027036.
      View in: PubMed
    46. Warshak CR, Eskander R, Hull AD, Scioscia AL, Mattrey RF, Benirschke K, Resnik R. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):573-81. PMID: 16946217.
      View in: PubMed